FIELD: immunology.
SUBSTANCE: present invention relates to the field of immunology. An anti-hIL-2 antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant vector and a method for producing an anti-hIL-2 antibody or an antigen-binding fragment thereof are disclosed. Also disclosed are a complex for use in minimizing Treg cell expansion and stimulation of CD8+ T cells and NK cells and a composition for use in the prevention or treatment of cancer. In addition, a composition for coadministration for use in treating cancer and a composition for use in enhancing vaccine efficacy are described.
EFFECT: invention can be used as an anti-cancer therapy.
15 cl, 10 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
